



CURRICULUM VITAE

Christopher Paul WILD

Dr Christopher Wild
Director, IARC

EDUCATION

1977 - 1980: Department of Pharmacology, University of Manchester, UK

QUALIFICATIONS

June 1980: Upper Second Class Honours Degree in Pharmacology, Faculty of Science, University of Manchester, UK

Jan 1984: PhD, Department of Oncology, Faculty of Medicine, University of Manchester, UK.
Title of thesis: 'Quantitation of alkylation damage by monoclonal antibodies'.

RESEARCH POSITIONS

1980 - 1984: Postgraduate Student (Paterson Laboratory Award), Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester, UK

1984 - 1986: Post-doctoral IARC Research Training Fellowship, International Agency for Research on Cancer, Lyon, France, Unit of Mechanisms of Carcinogenesis

1986 - 1987: Royal Society, European Exchange Fellowship, at the Division of Chemical Carcinogenesis, Netherlands National Cancer Institute, Amsterdam.

1987 - 1994: Scientist, Unit of Mechanisms of Carcinogenesis, International Agency for Research on Cancer, Lyon, France

1994 - 1996: Chief, Unit of Environmental Carcinogenesis, International Agency for Research on Cancer, Lyon, France

1996 - 2008: Professor of Molecular Epidemiology, Molecular Epidemiology Unit, Faculty of Medicine and Health, University of Leeds, Leeds, UK

2000 - 2007: Head of Academic Unit of Epidemiology and Health Services Research and subsequently Head of the Centre for Epidemiology and Biostatistics

2005 - 2008: Director of Leeds Institute of Genetics, Health and Therapeutics (LIGHT)

CURRENT POSITION

Jan. 2009 – to date: Director, International Agency for Research on Cancer (IARC)
Lyon, France

MEMBERSHIPS NATIONAL / INTERNATIONAL

- American Association for Cancer Research (AACR)
- British Association for Cancer Research (BACR)
- International Epidemiological Association (IEA)
- International Society of Exposure Science (ISES)
- Society for Social Medicine (SSM)

HONOURS / AWARDS

- Recipient of the Science Award for Outstanding Scientific Article 2003 from the Consultative Group on International Agricultural Research (CGIAR)
- Awarded the UK Molecular Epidemiology Group 10th Anniversary Medal in 2006 for the most significant contribution to Molecular Epidemiology in the UK over the last decade
- Fellow of the European Academy of Cancer Sciences, European Cancer Organisation (ECCO), Brussels, Belgium (from 2010)

SELECTED PUBLICATIONS

I. Books

1. Molecular Epidemiology of Chronic Disease (2008) Eds Christopher Wild, Sy Garte and Paolo Vineis. 416pp, Wiley press, ISBN: 978-0-470-02743-1

II. Original Peer-Reviewed Papers

1. Umbenhauer, D., **Wild, C.P.**, Montesano, R., Saffhill, R., Boyle, J.M., Huh, N., Kirstein, U., Thomale, J., Rajewsky, M.F. and Lu, S.H. (1985) ⁰⁶-Methyldeoxyguanosine in oesophageal DNA in populations at high risk of oesophageal cancer. *Int. J. Cancer*, **36**, 661-665
2. **Wild, C.P.**, Garner, R.C., Montesano, R. and Tursi, F. (1986) Aflatoxin B₁ binding to plasma albumin and liver DNA upon chronic administration to rats. *Carcinogenesis*, **7**, 853-858
3. **Wild, C.P.**, Jiang, Y.Z., Sabbioni, G., Chapot, B. and Montesano, R. (1990) Evaluation of methods for quantitation of aflatoxin-albumin adducts and their application to human exposure assessment. *Cancer Res.*, **50**, 245-251
4. **Wild, C.P.**, Jiang, Y.-Z., Allen, S.J., Jansen, L.A.M., Hall, A.J. and Montesano, R. (1990) Aflatoxin-albumin adducts in human sera from different regions of the world. *Carcinogenesis*, **11**, 2271-2274
5. Parkin, D.M., Srivatanakul, P., Khat, M., Chenvidhya, D., Chotiwan, P., Isiripong, S., L'Abbé, K. and **Wild, C.P.** (1991) Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. *Int. J. Cancer*, **48**, 323-328
6. Srivatanakul, P., Parkin, D.M., Khat, M., Chenvidhya, D., Chotiwan, P., Insiripong, S., L'Abbé, K. and **Wild, C.P.** (1991) Liver cancer in Thailand. II. A case-control study of hepatocellular carcinoma. *Int. J. Cancer*, **48**, 329-332
7. **Wild, C.P.**, Rasheed, F.N., Jawla, M.F.B., Hall, A.J., Jansen, L.A.M. and Montesano, R. (1991) *In utero* exposure to aflatoxin in West Africa. *Lancet*, **337**, 1602
8. **Wild, C.P.**, Hudson, G.J., Sabbioni, G., Chapot, B., Hall, A.J., Wogan, G.N., Whittle, H., Montesano, R. and Groopman, J.D. (1992) Dietary intake of aflatoxins and the level of albumin bound aflatoxin in peripheral blood in The Gambia, West Africa. *Cancer Epidemiol. Biomarkers Prev.*, **1**, 229-234
9. Groopman, J.D., Hall, A.J., Whittle, H., Hudson, G.J., Wogan, G.N., Montesano, R. and **Wild, C.P.** (1992) Molecular dosimetry of aflatoxin-*N*⁷-guanine in human urine obtained in The Gambia, West Africa. *Cancer Epidemiol. Biomarkers Prev.*, **1**, 221-227
10. Allen, S.J., **Wild, C.P.**, Wheeler, J.G., Riley, E.M., Montesano, R., Bennett, S., Whittle, H., Hall, A.J. and Greenwood, B.M. (1992) Aflatoxin exposure, malaria and hepatitis B infection in rural Gambian children. *Trans. Roy. Soc. Trop. Med. Hyg.*, **86**, 426-430
11. **Wild, C.P.**, Fortuin, M., Donato, F., Whittle, H.C., Hall, A.J., Wolf, C.R. and Montesano, R. (1993) Aflatoxin, liver enzymes and hepatitis B virus infection in Gambian children. *Cancer Epidemiol. Biomarkers Prev.*, **2**, 555-561

12. Kirby, G.M., Chemin, I., Montesano, R., Chisari, F.V., Lang, M.A. and **Wild, C.P.** (1994) Induction of specific cytochrome P450s involved in aflatoxin B₁ metabolism in hepatitis B virus transgenic mice. *Molec. Carcinogenesis*, **11**, 74-80
13. McGlynn, K.A., Rosvold, E.A., Lustbader, E.D., Hu, Y., Clapper, M.L., Zhou, T., **Wild, C.P.**, Xiao, X.-L., Baffoe-Bonnie, A., Ofori-Adjei, D., Chen, G.-C., London, W.T., Shen, F.M. and Buetow, K.H. (1995) Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B₁. *Proc. Natl. Acad. Sci. USA*, **92**, 2384-2387
14. **Wild, C.P.**, Ridanpää, M., Anttila, S., Lubin, R., Soussi, T., Husgafvel-Pursiainen and Vainio, H. (1995) p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. *Int. J. Cancer*, **64**, 176-181
15. **Wild, C.P.**, Hasegawa, R., Barraud, L., Chutimataewin, S., Chapot, B., Ito, N. and Montesano, R. (1996) Aflatoxin-albumin adducts: a basis for comparative carcinogenesis between animals and humans. *Cancer Epidemiol. Biomarkers Prev.*, **5**, 179-189
16. Chemin, I., Takahashi, S., Belloc, C., Lang, M.A., Ando, K., Guidotti, L.G., Chisari, F.V. and **Wild, C.P.** (1996) Differential induction of carcinogen metabolizing enzymes in a transgenic mouse model of fulminant hepatitis. *Hepatology*, **24**, 649-656
17. Kaplanski, C., Chisari, F.V. and **Wild, C.P.** (1997) Minisatellite rearrangements are increased in liver tumours induced by transplacental aflatoxin B₁ treatment of hepatitis B virus transgenic mice but not in spontaneously arising tumours. *Carcinogenesis*, **18**, 633-639
18. Kaplanski, C., Srivatanakul, P. and **Wild, C.P.** (1997) Frequent rearrangements at minisatellite loci D1S7 (1p33-35), D7S22 (7q36-ter) and D12S11 (12q24.3-ter) in hepatitis B virus positive hepatocellular carcinomas from Thai patients. *Int. J. Cancer*, **72**, 248-254
19. Montesano, R., Hainaut, P. and **Wild, C.P.** (1997) Hepatocellular carcinoma: from gene to public health. *J. Natl. Cancer Inst.*, **89**, 1844-1851
20. Kaplanski, C., **Wild, C.P.** and Sengstag, C. (1998) Rearrangements in minisatellite sequences induced by aflatoxin B₁ in a metabolically competent strain of *Saccharomyces cerevisiae*. *Carcinogenesis*, **19**, 1673-1678
21. **Wild, C.P.** and Hall, A.J. (1998) Hepatitis B virus and liver cancer - unanswered questions. *Cancer Surv.*, **33**, 35-54
22. Castegnaro, M., Garren, L., Galendo, D., Gelderblom, W.C.A., Chelule, P., Dutton, M.F. and **Wild, C.P.** (1998) Analytical method for the determination of sphinganine and sphingosine in serum as a potential biomarker for fumonisin exposure. *J. Chromatography B.*, **720**, 15-24
23. Lechevrel, M., Casson, A., Wolf, C.R., Hardie, L.J., Flinterman, M.B., Montesano, R. and **Wild, C.P.** (1999) Characterisation of cytochrome P450 expression in human oesophageal mucosa. *Carcinogenesis*, **20**, 243-248
24. Barraud, L., Guerret, S., Chevallier, M., Borel, C., Jamard, C., Trepo, C., **Wild, C.P.** and Cova, L. (1999) Enhanced duck hepatitis B virus gene expression following aflatoxin B₁ exposure. *Hepatology*, **29**, 1317-1323
25. Turner, P.C., Nikiema, P. and **Wild, C.P.** (1999) Fumonisin contamination of food: progress in development of biomarkers to better assess human health risks. *Mutat. Res.*, **443**, 81-93

26. **Wild, C.P.**, Yin, F., Turner, P.C., Chemin, I., Chapot, B., Mendy, M., Whittle, H., Kirk, G.D. and Hall, A.J. (2000) Environmental and genetic determinants of aflatoxin-albumin adducts in The Gambia. *Int. J. Cancer*, **86**, 1-7
27. Bani-Hani, K., Martin, I.G., Hardie, L.J., Mapstone, N., Briggs, J.A., Forman, D. and **Wild, C.P.** (2000) Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. *J. Natl. Cancer Inst.*, **92**, 1316-1321
28. **Wild, C.P.** and Hall, A.J. (2000) Primary prevention of hepatocellular carcinoma in developing countries. *Mutat. Res.*, **462**, 381-393
29. Turner, P.C., Mendy, M., Whittle, H., Fortuin, M., Hall, A.J. and **Wild, C.P.** (2000) Hepatitis B infection and aflatoxin biomarker levels in Gambian children. *Trop. Med. Int. Health*, **5**, 837-841
30. Allan, J.M., Hardie, L.J., Briggs, J.A., Davidson, L.A., Watson, J.P., Pearson, S.B., Muers, M.F. and **Wild, C.P.** (2001) Genetic alterations in bronchial mucosa and plasma DNA from individuals at high-risk of lung cancer. *Int. J. Cancer*, **91**, 359-365
31. Meko, F.A., Hardie, L.J., Evans, S.W. and **Wild, C.P.** (2001) Deoxynivalenol-induced immunomodulation of human lymphocyte proliferation and cytokine production. *Food Chem. Toxicol.*, **39**, 827-836
32. Allan, J.M., **Wild, C.P.**, Rollinson, S., Willett, E.V., Moorman, A.V., Dovey, G.J., Roddam, P.L., Roman, E., Cartwright, R.A. and Morgan, G.J. (2001) Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukaemia. *Proc. Natl. Acad. Sci.*, **98**, 11592-11597
33. **Wild, C.P.**, Law, G.R. and Roman, E. (2002) Molecular epidemiology and cancer: promising areas for future research in the post-genomic era. *Mutat. Res.*, **499**, 3-12
34. Gong, Y.Y., Cardwell, K., Hounsa, A., Egal, S., Turner, P.C., Hall, A.J., and **Wild, C.P.** (2002) Dietary aflatoxin exposure and impaired growth in young children from Benin and Togo: cross sectional study. *Brit. Med. J.*, **325**, 20-21
35. **Wild, C.P.** and Turner P.C. (2002) The toxicology of aflatoxins as a basis for public health decisions. *Mutagenesis*, **17**, 471-481
36. Meko, F.A., Turner, P.C., Ashcroft, A.E., Miller, J.D., Qiao, Y.-L., Roth, M.J. and **Wild, C.P.** (2003) Development of a urinary biomarker of human exposure to deoxynivalenol. *Food Chem. Toxicol.*, **41**, 265-273
37. Turner, P.C., Moore, S.E., Hall, A.J., Prentice, A.M. and **Wild, C.P.** (2003) Modification of immune function through exposure to dietary aflatoxin in Gambian children. *Environ. Health Perspect.*, **111**, 217-220
38. Olliver, J., **Wild, C.P.**, Sahay, P., Dexter, S. and Hardie, L.J. (2003) Chromoendoscopy with methylene blue and associated DNA damage in Barrett's oesophagus. *Lancet*, **362**, 373-374
39. Gong, Y.Y., Egal, S., Hounsa, A., Turner, P.C., Hall, A.J., Cardwell, K.F. and **Wild, C.P.** (2003) Determinants of aflatoxin exposure in young children from Benin and Togo, West Africa: the critical role of weaning. *Int. J. Epidemiol.*, **32**, 556-562
40. **Wild, C.P.** and Hardie, L.J. (2003) Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. *Nat. Rev. Cancer*, **3**, 676-684

41. Olliver, J.R., Hardie, L.J., Dexter, S., Chalmers, D. and **Wild, C.P.** (2003) DNA damage levels are raised in Barrett's oesophageal mucosa relative to squamous epithelium of the oesophagus. *Biomarkers*, **8**, 509-521
42. Jolly, A.J., **Wild, C.P.** and Hardie, L.J. (2004) Acid and bile salts increase DNA damage levels in human oesophageal cell lines. *Mutagenesis*, **19**, 319-324
43. Fountoulakis, A., Martin, I.G., White, K.L.M., Dixon, M.F., Cade, J.E., Sue-Ling, H.M. and **Wild, C.P.** (2004) Plasma and esophageal mucosal levels of vitamin C: Role in the pathogenesis and neoplastic progression of Barrett's esophagus. *Dig. Dis. Sci.*, **49**, 914-919
44. Gong, Y.Y., Hounsa, A., Egal, S., Turner, P.C., Sutcliffe, A.E., Hall, A.J., Cardwell, K. and **Wild, C.P.** (2004) Post-weaning exposure to aflatoxin results in impaired child growth: a longitudinal study in Benin, West Africa. *Environ. Health Perspect.*, **112**, 1334-1338
45. Allan, J.M., Smith, A.G., Wheatley, K., Hills, R.K., Travis, L.B., Hill, D.A., Swirsky, D.M., Morgan, G.J. and **Wild, C.P.** (2004) Genetic variation in *XPD* predicts treatment outcome and risk of acute myeloid leukaemia following chemotherapy. *Blood*, **104**, 3872-3877
46. Olliver, J.R., Hardie, L.J., Gong, Y.Y., Dexter, S., Chalmers, D., Harris, K.M. and **Wild, C.P.** (2005) Risk factors, DNA damage and disease progression in Barrett's esophagus. *Cancer Epidemiol. Biomarkers Prev.*, **14**, 620-625
47. Kirk, G.D., Turner, P.C., Gong, Y., Lesi, O.A., Mendy, M., Goedert, J.J., Hainaut, P., Montesano, R. and **Wild, C.P.** (2005) Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. *Cancer Epidemiol. Biomarkers Prev.*, **14**, 373-379
48. Turner P.C., Sylla A., Gong Y.Y., Diallo M.S., Sutcliffe A.E., Hall A.J., and **Wild, C.P.** (2005) Reduction in exposure to carcinogenic aflatoxins by simple post-harvest intervention measures in West Africa. *Lancet*, **365**, 1950-1956
49. Turner, P.C., Sylla, A., Kuang, S.Y., Marchant, C.L., Diallo, M.S., Hall, A.J., Groopman, J.D. and **Wild, C.P.** (2005) Absence of TP53 codon 249 mutations in young Guinean children with high aflatoxin exposure. *Cancer Epidemiol. Biomarkers Prev.*, **14**, 2053-2055
50. Cook, M.B., **Wild, C.P.** and Forman, D. (2005) A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease and nonerosive reflux disease. *Am. J. Epidemiol.*, **162**, 1-12
51. Murray, L., Sedo, A., Scott, M., McManus, D., Sloan, J.M., Hardie, L.J., Forman, D. and **Wild, C.P.** (2006) TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. *Gut*, **55**, 1390-1397
52. **Wild, C.P.** (2007) Aflatoxin exposure in developing countries: the critical interface of agriculture and health. *Food Nutr. Bull.*, **28**, S372-S380
53. Turner, P.C., Collinson, A.C., Cheung, Y.C., Gong, Y.Y., Hall, A.J., Prentice, A.M. and **Wild, C.P.** (2007) Aflatoxin exposure *in utero* causes growth faltering in Gambian infants. *Int. J. Epidemiol.*, **36**, 1119-1125
54. Cook, M.B., **Wild, C.P.**, Everett, S.M., Hardie, L.J., Bani-Hani, K.E., Martin, I.G. and Forman, D. (2007) Risk of mortality and cancer incidence in Barrett's Oesophagus. *Cancer Epidemiol. Biomarkers Prev.*, **16**, 2090-2096

55. Groopman, J.D., Kensler, T.W. and **Wild, C.P.** (2008) Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries. *Annual Reviews Public Health*, **29**, 187-203
56. Turner, P.C., Burley, V.J., Rothwell, J.A., White, K.L.M., Cade, J.E. and **Wild, C.P.** (2008) Dietary wheat reduction decreases the level of urinary deoxynivalenol in UK adults. *J. Expo. Sci. Epidemiol.*, **18**, 392-399
57. Turner, P.C., Rothwell, J.A., White, K.L.M., Gong, Y.Y., Cade, J.E. and **Wild, C.P.** (2008) Urinary deoxynivalenol is correlated with cereal intake in individuals from the United Kingdom. *Environ. Health Perspect.*, **116**, 21-25
58. Gong, Y.Y., Torres-Sanchez, L., Lopez-Carrillo, L., Peng, J.H., Sutcliffe, A.E., White, K.L.M., Humpf, H.U., Turner, P.C. and **Wild, C.P.** (2008) Association between tortilla consumption and human urinary fumonisin B₁ levels in a Mexican population. *Cancer Epidemiol. Biomarkers Prev.*, **17**, 688-694
59. Cook, M.B. Greenwood, D.C., Hardie, L.J., **Wild, C.P.** and Forman, D (2008) A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's Esophagus. *Amer. J. Gastroenterology*, **103**, 292-300
60. McCoy, L.F., Scholl, P.F., Sutcliffe, A.E., Kieszak, S.M., Powers, C.D., Rogers, H.S., Gong, Y.Y., Groopman, J.D., **Wild, C.P.** and Schleicher, R.L. (2008) Human aflatoxin albumin adducts quantitatively compared by ELISA, HPLC with fluorescence detection, and HPLC with isotope dilution mass spectrometry. *Cancer Epidemiol. Biomarkers Prev.*, **17**, 1653-1657
61. CARE Study Group (2009) Maternal caffeine intake during pregnancy and risk of fetal growth restriction: a large prospective observational study. *BMJ*, **337**, a2332
62. **Wild, C.P.** (2009) Environmental exposure measurement in cancer epidemiology. *Mutagenesis*, **24**, 117-125
63. Jolly, A.J., **Wild, C.P.** and Hardie, L.J. (2009) Sodium deoxycholate causes nitric oxide mediated DNA damage in oesophageal cells. *Free Radic. Res.*, **43**, 234-240
64. Sturmey, R.G., **Wild, C.P.** and Hardie, L.J. (2009) Removal of red light minimizes methylene blue-stimulated DNA damage in oesophageal cells: implications for chromoendoscopy. *Mutagenesis*, **24**, 253-258
65. **Wild, C.P.** and Montesano, R. (2009) A model of interactions: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. *Cancer Letters*, **286**, 22-28
66. Turner, P.C., Taylor, F., White, K., Cade, J. and **Wild, C.P.** (2009) A comparison of 24-hour urinary deoxynivalenol with recent versus average cereal consumption for UK adults. *Br. J. Nutr.*, **102**, 1276-1279
67. **Wild, C.P.** and Gong, Y.Y. (2010) Mycotoxins and human disease: a largely ignored global health issue. *Carcinogenesis*, **31**, 71-82
68. van der Westhuizen, L., Shephard, G.S., Rheeder, J.P., Burger, H.-M., Gelderblom, W.C.A., **Wild, C.P.** and Gong, Y.Y. (2010) Simple intervention method to reduce fumonisin exposure in a subsistence maize farming community of South Africa. *Food Addit. Contam.*, **27**, 1582-1588
69. van der Westhuizen, L., Shephard, S.S., Burger, H.-M., Rheeder, J.P., Gelderblom, W.C.A., **Wild, C.P.** and Gong, Y.Y. (2011) Fumonisin B₁ as a urinary biomarker of exposure in a maize

intervention study among South African subsistence farmers. *Cancer Epidemiol. Biomarkers Prev.*, **20**(3), 483-9

70. **Wild, C.P.** (2011) Future research perspectives on environment and health: the requirement for a more expansive concept of translational cancer research. *Env. Health* **10**(Suppl 1), S15
71. Sylla, B.S. and **Wild C.P.** A million Africans a year dying from cancer by 2030: what can cancer research and control offer to the continent? *Int. J. Cancer*, in press

III. Letters to the Editor

1. **Wild, C.P.** and Cogliano, V. (2011) A plea on behalf of expert evaluation and the experts involved. Letter to the Editor. *Int. J. Epidemiol.*, **40**, 253-261

IV. Editorials

1. **Wild, C.P.** and Kleinjans, J. (2003) Children and increased susceptibility to environmental carcinogens: evidence or empathy? Editorial: *Cancer Epidemiol. Biomarkers Prev.*, **12**, 1389-1394
2. **Wild, C.P.** (2005) Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in Molecular Epidemiology. *Cancer Epidemiol. Biomarkers Prev.*, **14**, 1847-1850
3. **Wild, C.P.** (2010) OMICS technologies: an opportunity for "two-way" translation from basic science to both clinical and population-based research. *Occup. Environ. Med.*, **67**, 75-76
4. **Wild, C.P.** (2011) How much of a contribution do exposures experienced between conception and adolescence make to the burden of cancer in adults? *Cancer Epidemiol. Biomarkers Prev.*, **20**(4), 580-1